10:58 AM EDT, 03/23/2026 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) and Eli Lilly ( LLY ) will face a multibillion-dollar class action accusing them of concealing diabetes drug Actos' bladder cancer risk after the US Supreme Court rejected their appeal, Bloomberg reported Monday, citing a court order. The high court rejected the companies' argument that the lawsuit should...

LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:   Sand Grove Capital Management LLP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming...

LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...

LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:   Sand Grove Capital Management LLP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming...